, Volume 55, Issue 1, pp 173–178 | Cite as

Combination therapy with GLP-1 analogues and SGLT-2 inhibitors in the management of diabesity: the real world experience

  • Herpreet Deol
  • Leoni Lekkakou
  • Ananth K. Viswanath
  • Joseph M. PappachanEmail author
Original Article


Diabesity—obesity resulting in diabetes—is a major health problem globally because of the obesity epidemic. Several anti-diabetic medications cause weight gain and may worsen obesity, and possibly diabeisty. Two recent small retrospective cohort studies showed weight loss and diabetes improvement with combination of glucagon-like peptide-1 (GLP-1) agonists and sodium-glucose co-transporter type-2 (SGLT-2) inhibitors in obese subjects. We assessed the effect of combination therapy with GLP-1 agonists and SGLT-2 inhibitors in the management of diabesity in a retrospective study at the Wolverhampton Diabetes Centre. Out of 79 patients on this combination regimen with other anti-diabetic medications, 37 cases who had follow up at 3–6 months were studied. Mean age and duration of follow up were 57.4 (+/−7.8) and 139 (+/−32.6) days, respectively. Twenty-two patients (59.5 %) were Asians. Statistically significant improvements in clinical parameters such as body weight reduction (3.07 kg), glycated haemoglobin (HbA1c) reduction (1.05 %), lower BMI (−1.13 kg/M2) and insulin dose reduction (6.8 units) were observed (p < 0.05 for all) in patients on combination regimen. Linear regression analysis showed that baseline HbA1c and baseline insulin dose were independent predictors of HbA1c reduction and insulin dose reduction, respectively. Our results suggest that combination therapy with GLP-1 agonists and SGLT-2 inhibitors is a promising option for patients with diabesity.


Diabesity Glucagon-like peptide-1 (GLP-1) agonist Sodium-glucose co-transporter type-2 (SGLT-2) inhibitors Management of diabesity Anti-diabetic combination regimen 



No funding was received for this work

Compliance with ethical standards

Conflict of interest

Ananth K Viswanath received lecture fees from MSD, Novo Nordisk, Takeda, Eilly Lilly, Jansen and sponsorship from Novo Nordisk, Takeda, Novartis and Jansen to attend international conferences. The remaining authors have no conflicts of interest to declare.


Both the first and second authors contributed equally to the research and preparation of the manuscript.


  1. 1.
    World Health Organization. Obesity and overweight. Geneva, Switzerland: World Health Organization, 2015. Accessed 30 March 2016
  2. 2.
    E.A. Sims, E. Danforth Jr, E.S. Horton, G.A. Bray, J.A. Glennon, L.B. Salans, Endocrine and metabolic effects of experimental obesity in man. Recent Prog. Horm. Res. 29, 457–496 (1973)PubMedGoogle Scholar
  3. 3.
    P.R. Schauer, D.L. Bhatt, J.P. Kirwan, K. Wolski, S.A. Brethauer, S.D. Navaneethan, A. Aminian, C.E. Pothier, E.S. Kim, S.E. Nissen, S.R. Kashyap, STAMPEDE Investigators. Bariatric surgery versus intensive medical therapy for diabetes—3-year outcomes. N. Engl. J. Med. 370, 2002–2013 (2014)CrossRefPubMedGoogle Scholar
  4. 4.
    G. Mingrone, S. Panunzi, A. De Gaetano, C. Guidone, A. Iaconelli, G. Nanni et al., Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial. Lancet 386(9997), 964–973 (2015)CrossRefPubMedGoogle Scholar
  5. 5.
    G.F. Paulus, L.E. de Vaan, F.J. Verdam, N.D. Bouvy, T.A. Ambergen, L.W. van Heurn, Bariatric surgery in morbidly obese adolescents: a systematic review and meta-analysis. Obes. Surg. 25, 860–878 (2015)CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    R.M. Saroka, M.P. Kane, R.S. Busch, J. Watsky, R.A. Hamilton, SGLT-2 inhibitor therapy added to GLP-1 agonist therapy in the management of T2DM. Endocr. Pract. 21, 1315–1322 (2015)CrossRefPubMedGoogle Scholar
  7. 7.
    K. Kaku, H. Maegawa, Y. Tanizawa, A. Kiyosue, Y. Ide, T. Tokudome, Y. Hoshino, J. Yang, A.M. Langkilde, Dapagliflozin as monotherapy or combination therapy in Japanese patients with type 2 diabetes: an open-label study. Diabetes Ther 5, 415–433 (2014)CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    L. Curtis, M.A. Humayun, J. Walker, K. Hampton, H. Partridge, Addition of SGLT2 inhibitor to GLP-1 agonist therapy in people with type 2 diabetes and suboptimal glycaemic control. Practical Diabetes 33, 129–132 (2016)CrossRefGoogle Scholar
  9. 9.
    K. Esposito, P. Chiodini, A. Capuano, M.I. Maiorino, G. Bellastella, D. Giugliano, Baseline glycemic parameters predict the hemoglobin A1c response to DPP-4 inhibitors : meta-regression analysis of 78 randomized controlled trials with 20,053 patients. Endocrine 46, 43–51 (2014)CrossRefPubMedGoogle Scholar
  10. 10.
    R.R. Henry, J.B. Buse, G. Sesti, M.J. Davies, K.H. Jensen, J. Brett, R.E. Pratley, Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobinA(1c): a meta-analysis of the liraglutide development program. Endocr. Pract. 17, 906–913 (2011)CrossRefPubMedGoogle Scholar
  11. 11.
    J. Rosenstock, L. Hansen, P. Zee, Y. Li, W. Cook, B. Hirshberg, N. Iqbal, Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. Diabetes Care 38, 376–383 (2015)CrossRefPubMedGoogle Scholar
  12. 12.
    R. Huxley, W.P. James, F. Barzi, J.V. Patel, S.A. Lear, P. Suriyawongpaisal, E. Janus, I. Caterson, P. Zimmet, D. Prabhakaran, S. Reddy, M. Woodward, Obesity in Asia Collaboration. Ethnic comparisons of the cross-sectional relationships between measures of body size with diabetes and hypertension. Obes. Rev. 9(Suppl 1), 53–61 (2008)CrossRefPubMedGoogle Scholar
  13. 13.
    S. Haldar, S.C. Chia, C.J. Henry, Body composition in Asians and Caucasians: comparative analyses and influences on cardiometabolic outcomes. Adv. Food Nutr. Res. 75, 97–154 (2015)CrossRefPubMedGoogle Scholar
  14. 14.
    D.S. Shyangdan, O.A. Uthman, N. Waugh, SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis. BMJ Open 6, e009417 (2016)CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    N.M. Maruthur, E. Tseng, S. Hutfless, L.M. Wilson, C. Suarez-Cuervo, Z. Berger, Y. Chu, E. Iyoha, J.B. Segal, S. Bolen, Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis. Ann. Intern. Med. 164, 740–751 (2016)CrossRefPubMedGoogle Scholar
  16. 16.
    B. Zinman, C. Wanner, J.M. Lachin, D. Fitchett, E. Bluhmki, S. Hantel et al., Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373, 2117–2128 (2015)CrossRefPubMedGoogle Scholar
  17. 17.
    C. Wanner, S.E. Inzucchi, J.M. Lachin, D. Fitchett, M. von Eynatten, M. Mattheus et al., Empagliflozin and progression of kidney disease in type 2 diabetes. N. Engl. J. Med. 375, 323–334 (2016)CrossRefPubMedGoogle Scholar
  18. 18.
    S.P. Marso, G.H. Daniels, K. Brown-Frandsen, P. Kristensen, J.F. Mann, M.A. Nauck et al., Liraglutide and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 375, 311–322 (2016)CrossRefPubMedGoogle Scholar
  19. 19.
    M. May, C. Schindler, Clinically and pharmacologically relevant interactions of antidiabetic drugs. Ther. Adv. Endocrinol. Metab. 7, 69–83 (2016)CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    S.I. Taylor, J.E. Blau, K.I. Rother, SGLT2 inhibitors may predispose to ketoacidosis. J. Clin. Endocrinol. Metab. 100, 2849–2852 (2015)CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    M.M. Smits, L. Tonneijck, M.H. Muskiet, M.H. Kramer, D.L. Cahen, D.H. van Raalte, Gastrointestinal actions of glucagon-like peptide-1-based therapies: glycaemic control beyond the pancreas. Diabetes Obes. Metab. 18, 224–235 (2016)CrossRefPubMedGoogle Scholar
  22. 22.
    F. Sun, S. Wu, S. Guo, K. Yu, Z. Yang, L. Li, Y. Zhang, L. Ji, S. Zhan, Effect of GLP-1 receptor agonists on waist circumference among type 2 diabetes patients: a systematic review and network meta-analysis. Endocrine 48, 794–803 (2015)CrossRefPubMedGoogle Scholar
  23. 23.
    R.P.Monica Reddy, S.E. Inzucchi, SGLT2 inhibitors in the management of type 2 diabetes. Endocrine 53, 364–372 (2016)CrossRefGoogle Scholar
  24. 24.
    Y.G. Kim, S. Hahn, T.J. Oh, K.S. Park, Y.M. Cho, Differences in the HbA1c-lowering efficacy of glucagon-like peptide-1 analogues between Asians and non-Asians: a systematic review and meta-analysis. Diabetes Obes. Metab. 16, 900–909 (2014)CrossRefPubMedGoogle Scholar
  25. 25.
    S.E. Inzucchi, R.M. Bergenstal, J.B. Buse, M. Diamant, E. Ferrannini, M. Nauck et al., Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 38, 140–149 (2015)CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  1. 1.Department of Endocrinology & DiabetesNew Cross Hospital, The Royal Wolverhampton Hospitals NHS TrustWolverhamptonUK

Personalised recommendations